Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)J. Jean Cui, Martin P. Edwards, Michelle Tran‐Dubé et al.|Journal of Medicinal Chemistry|2011Cited by 924
Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to CrizotinibQinhua Huang, Martin P. Edwards, Kevin D. Bunker et al.|Journal of Medicinal Chemistry|2014Cited by 118